IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA
- Conditions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 200
- Registration Number
- NCT04446702
- Locations
- 🇧🇷
Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP), San Paolo, Brazil
A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.
- Conditions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 114
- Registration Number
- NCT04396704
- Locations
- 🇬🇧
North Staffordshire Rehabilitation Centre. Midlands Partnership NHS Foundation Trust., Stafford, United Kingdom
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 247
- Registration Number
- NCT04353765
- Locations
- 🇺🇸
McKesson Life Sciences, The Woodlands, Texas, United States
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
- Conditions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT04340336
- Locations
- 🇮🇹
Ubaldo Del Carro, Milano, Italy
🇮🇹Marecello Esposito, Milano, Italy
🇮🇹Morena Giovannelli, Roma, Italy
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
- Conditions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT04106349
- Locations
- 🇧🇪
Chirec Delta, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇪Virga Jessa Ziekenhuis, Hasselt, Belgium
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 770
- Registration Number
- NCT04083235
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States
Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
- Conditions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 438
- Registration Number
- NCT04050527
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Riverhills Healthcare, Cincinnati, Ohio, United States
🇺🇸OrthoNeuro, Columbus, Ohio, United States
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
- Conditions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Ipsen
- Registration Number
- NCT04003519
Spasticity and Treatment Satisfaction Among Stroke Survivors
- Conditions
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT03995524
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
- Conditions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 54
- Registration Number
- NCT03947762
- Locations
- 🇪🇸
Hospital Basurto, Bilbao, Spain
🇪🇸Hospital General Ciudad Real, Ciudad Real, Spain
🇪🇸Hospital Torrecardenas, Almería, Spain